6LJ0 Stock Chart & Stats
€0.05
>-€0.01(-14.52%)
At close: 4:00 PM EST
€0.05
>-€0.01(-14.52%)
Day’s Range― - ―
52-Week Range€0.05 - €0.05
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€3.49M
Enterprise Value€1.94
Total Cash (Recent Filing)€2.45M
Total Debt (Recent Filing)€1.19M
Price to Earnings (P/E)―
Beta0.23
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding13,692,796
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.66
Price to Sales (P/S)0.00
P/FCF Ratio-0.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Monetization Of Nanotech Assets Via Sale To AzuritySelling the nanotechnologies unit generates immediate non-dilutive cash and a structured milestone/royalty stream that can materially extend runway. This structural monetization reduces near-term financing pressure and converts a high-cost R&D asset into contingent, multi-year cash flows.
Modest Leverage With Low Absolute DebtLow absolute debt and a sub-0.4 debt/equity profile limit interest burden and short-term solvency risk. For a pre-commercial biotech, modest leverage preserves flexibility to execute corporate actions and reduces near-term creditors' pressure while management pursues strategic transactions.
Material Reduction In Losses And Cash Burn TrendConsistent, multi-year reduction in operating losses and cash burn indicates better cost discipline or narrowing pipeline expenses. This structural improvement enhances the company's ability to survive until strategic deals close and reduces the quantum of external capital required.
Bears Say
No Revenue And Persistent Net LossesWith zero reported revenue and recurring negative net income, the firm's business model currently lacks operating cash generation. Over the medium term this forces reliance on external financing or asset monetizations and leaves limited visibility into a sustainable path to profitability.
Severely Depleted Equity And Listing-compliance RiskEquity erosion to roughly $3M materially reduces financial flexibility and triggers formal exchange remediation. The ongoing compliance timeline creates execution risk, potential delisting consequences, and constrains strategic options, making durable recovery contingent on successful remediation or financing.
Divestiture Removes Core LNC Platform And Future UpsideTransferring the LNC platform and lead candidate reduces Matinas's future product-development optionality and long-term upside from proprietary technology. While monetizing assets improves liquidity, it structurally narrows the company's R&D-led value creation path and shifts future returns to contingent royalties.
Matinas BioPharma News
6LJ0 FAQ
What was Matinas BioPharma’s price range in the past 12 months?
Matinas BioPharma lowest stock price was €0.05 and its highest was €0.05 in the past 12 months.
What is Matinas BioPharma’s market cap?
Matinas BioPharma’s market cap is €3.49M.
When is Matinas BioPharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Matinas BioPharma’s earnings last quarter?
Currently, no data Available
Is Matinas BioPharma overvalued?
According to Wall Street analysts Matinas BioPharma’s price is currently Overvalued.
Does Matinas BioPharma pay dividends?
Matinas BioPharma does not currently pay dividends.
What is Matinas BioPharma’s EPS estimate?
Matinas BioPharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Matinas BioPharma have?
Matinas BioPharma has 13,692,796 shares outstanding.
What happened to Matinas BioPharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Matinas BioPharma?
Currently, no hedge funds are holding shares in DE:6LJ0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Matinas BioPharma
Matinas BioPharma Holdings, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying and advancing a range of potential therapeutic products. The company's innovative Lipid Nanocrystal (LNC) platform technology underpins its product development efforts. This sophisticated LNC delivery system leverages lipid nano-crystals to transport a diverse array of therapeutic agents, including small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its primary experimental drug, LYPDISO, is a proprietary, prescription-grade omega-3 free fatty acid compound engineered to address cardiovascular and metabolic disorders. Matinas BioPharma is also advancing MAT2203, an orally administered version of amphotericin B. This candidate is currently in Phase II clinical trials, where it is being evaluated for its ability to prevent invasive fungal infections in patients undergoing immunosuppressive treatment. Furthermore, MAT2501, an oral formulation of the broad-spectrum aminoglycoside antibiotic amikacin, has successfully completed Phase I clinical trials. Its aim is to combat a spectrum of multidrug-resistant bacterial infections, such as non-tuberculous mycobacterium, multidrug-resistant gram-negative, and intracellular bacterial pathogens. The company actively engages in collaborations, including a research partnership with the National Institute of Allergy and Infectious Diseases (NIAID) to further the development of Gilead's antiviral drug, remdesivir. Additionally, it has a feasibility collaboration with Genentech, Inc. focused on creating new oral drug formulations. Established in 2013, Matinas BioPharma maintains its corporate headquarters in Bedminster, New Jersey.